To include your compound in the COVID-19 Resource Center, submit it here.

Hedging against academic risk

Investors in early stage companies must often take a leap of faith that the academic research behind a company's strategy is well validated and can be reproduced by independent hands. But according to Atlas Venturepartner Bruce Booth, most academic studies are not conducted with sufficient rigor to warrant such a leap.

"Validation is a huge challenge to any translational effort," Booth told SciBX. "The problem is not being able to reproduce academic results" outside the original laboratory.

Booth said that the "unspoken rule" among early stage VCs is that at

Read the full 882 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers